Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Gross Profit | -12,000 | 20% |
| Cost of Revenue | 12,000 | 20% |
| Operating expense | 3.7M | 22.8% |
| Net Income | -3.5M | 34.6% |
| EBITDA | -3.5M | 34.9% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 33M | 7.2% |
| Total Liabilities | 2.8M | 42.9% |
| Total Equity | 30M | 4.9% |
| Shares Outstanding | 36M | 114.4% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -2.6M | 10.5% |
| Cash from investing | -1.3M | 94.7% |
| Cash from financing | 4.8M | 82.9% |
EPS
Financial Highlights for Microbot Medical in Q2 '25
Gross Profit stood at -12,000, marking a 20% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 12,000, a -20% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 3.7M, showing a 22.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -3.5M, showing a -34.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -3.5M, showing a -34.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Microbot Medical faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
